Clinical Trials Arena November 1, 2024
The data was shared at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain, on 31 October.
Sunbird Bio has unveiled new data demonstrating that its diagnostic technology classified Parkinson’s disease-positive blood samples with 86% accuracy through the direct detection of aggregated alpha synuclein proteins.
Data from the study was showcased at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain, on 31 October. The study evaluated whether extracellular vesicle (EV)-bound alpha-synuclein proteins in the blood could serve as a reliable marker for detecting alpha-synuclein in the brain – a key indicator of Parkinson’s disease. Currently, Parkinson’s lacks an approved blood-based diagnostic test, despite research showing that brain-aggregation of a-synuclein is a hallmark of the disease....
Today's Sponsors
Today's Sponsor